

# Thomas M Bridges

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2629740/publications.pdf>

Version: 2024-02-01

70  
papers

2,788  
citations

186265

28  
h-index

182427

51  
g-index

74  
all docs

74  
docs citations

74  
times ranked

2222  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Selective Allosteric Potentiator of the M <sub>1</sub> Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning. <i>Journal of Neuroscience</i> , 2009, 29, 14271-14286.	3.6	217
2	Application of Combinatorial Chemistry Science on Modern Drug Discovery. <i>ACS Combinatorial Science</i> , 2008, 10, 345-354.	3.3	206
3	Centrally Active Allosteric Potentiators of the M <sub>4</sub> Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 941-953.	2.5	177
4	G-Protein-Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms. <i>ACS Chemical Biology</i> , 2008, 3, 530-541.	3.4	154
5	Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. <i>Chemical Reviews</i> , 2016, 116, 6707-6741.	47.7	151
6	Discovery and Characterization of Novel Allosteric Potentiators of M <sub>1</sub> Muscarinic Receptors Reveals Multiple Modes of Activity. <i>Molecular Pharmacology</i> , 2009, 75, 577-588.	2.3	135
7	Biased mGlu 5 -Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents. <i>Neuron</i> , 2015, 86, 1029-1040.	8.1	121
8	Selective Activation of M <sub>4</sub> Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents. <i>ACS Chemical Neuroscience</i> , 2014, 5, 920-942.	3.5	116
9	Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity. <i>Biological Psychiatry</i> , 2013, 73, 501-509.	1.3	95
10	Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy <i>N</i> -Benzyl Isatins. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3445-3448.	6.4	92
11	Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100. <i>Neuropsychopharmacology</i> , 2014, 39, 1578-1593.	5.4	91
12	Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M <sub>1</sub> Receptor Function in the Central Nervous System. <i>ACS Chemical Neuroscience</i> , 2010, 1, 104-121.	3.5	88
13	The antipsychotic potential of muscarinic allosteric modulation. <i>Drug News and Perspectives</i> , 2010, 23, 229.	1.5	53
14	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1972-1975.	2.2	51
15	mGlu <sub>5</sub> positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1990-2004.	2.9	48
16	Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 558-562.	2.2	43
17	Discovery of VU0467485/AZ13713945: An M <sub>4</sub> PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 233-238.	2.8	43
18	Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1703-1714.	3.3	42

#	ARTICLE	IF	CITATIONS
19	Discovery of VU0409551/JNJ-46778212: An mGlu <sub>5</sub> Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 716-720.	2.8	41
20	Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14078-14083.	7.1	41
21	Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5084-5088.	2.2	39
22	Design and Synthesis of <i>N</i> -Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu <sub>3</sub> NAMs. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 925-930.	2.8	38
23	Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5439-5442.	2.2	37
24	Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: Development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 346-350.	2.2	37
25	Synthesis and Structure-Activity Relationships of Allosteric Potentiators of the M <sub>4</sub> Muscarinic Acetylcholine Receptor. <i>ChemMedChem</i> , 2009, 4, 1600-1607.	3.2	35
26	Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. <i>Neuropharmacology</i> , 2018, 128, 492-502.	4.1	35
27	Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma. , 2018, 59, 446.		35
28	Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6451-6455.	2.2	32
29	Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 171-175.	2.2	32
30	Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5617-5622.	2.2	29
31	Chemical Modification of the M <sub>1</sub> Agonist VU0364572 Reveals Molecular Switches in Pharmacology and a Bitopic Binding Mode. <i>ACS Chemical Neuroscience</i> , 2012, 3, 1025-1036.	3.5	29
32	Exploration of Allosteric Agonism Structure-Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu <sub>5</sub> ) Positive Allosteric Modulators (PAMs): Discovery of 5-((3-Fluorophenyl)ethynyl)- <i>N</i> -(3-methyloxetan-3-yl)picolinamide (ML254). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7976-7996.	6.4	28
33	Preparation of Unsymmetrical 1,2,4,5-Tetrazines via a Mild Suzuki Cross-Coupling Reaction. <i>Organic Letters</i> , 2017, 19, 5693-5696.	4.6	27
34	State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects. <i>Neuropharmacology</i> , 2016, 102, 244-253.	4.1	23
35	Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1356-1359.	2.2	23
36	Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3029-3033.	2.2	22

#	ARTICLE	IF	CITATIONS
37	Further optimization of the M5 NAM MLPCN probe ML375: Tactics and challenges. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 690-694.	2.2	20
38	Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. <i>Current Opinion in Molecular Therapeutics</i> , 2008, 10, 591-601.	2.8	18
39	Optimization of M 4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2296-2301.	2.2	17
40	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidone-derived tertiary amides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5179-5184.	2.2	17
41	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidone-derived amides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2990-2995.	2.2	16
42	Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M 4 positive allosteric modulator (PAM) chemotype via scaffold hopping. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4999-5001.	2.2	15
43	Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1873-1879.	3.5	13
44	Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates. <i>Neuropsychopharmacology</i> , 2020, 45, 2219-2228.	5.4	13
45	Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4282-4286.	2.2	11
46	Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. <i>British Journal of Ophthalmology</i> , 2022, 106, 288-296.	3.9	11
47	Discovery of the First Selective M <sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic Efficacy. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1306-1321.	4.9	11
48	novel, CNS penetrant pan-muscarinic antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3576-3581.	2.2	10
49	A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1718-1726.	3.3	9
50	Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1310-1317.	2.2	9
51	Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4274-4279.	2.2	8
52	Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model. , 2021, 62, 8.		8
53	Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3641-3646.	2.2	7
54	Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3515-3519.	2.2	7

#	ARTICLE	IF	CITATIONS
55	Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 429-434.	2.2	7
56	Discovery of a novel 3,4-dimethylcinnoline carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126678.	2.2	7
57	<i>In Vitro</i> to <i>In Vivo</i> Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 442-452.	4.9	7
58	VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1714-1718.	2.2	6
59	Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1342-1349.	2.8	6
60	Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5115-5120.	2.2	5
61	Towards a TREK-1/2 (TWIK-Related K <sup>+</sup> Channel 1 and 2) dual activator tool compound: Multi-dimensional optimization of BL-1249. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1601-1604.	2.2	5
62	SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2224-2228.	2.2	4
63	Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in $\beta^2$ -amino carboxamide-harboring ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 362-366.	2.2	4
64	Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126811.	2.2	3
65	Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2479-2483.	2.2	2
66	Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126812.	2.2	2
67	Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 56, 128479.	2.2	1
68	Molecule of the Month. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1152-1152.	2.1	0
69	Development of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes - Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 53, 128416.	2.2	0
70	M4 muscarinic acetylcholine receptor modulation of associative learning and behavioral flexibility in a novel touchscreen cognitive assessment (845.8). <i>FASEB Journal</i> , 2014, 28, 845.8.	0.5	0